ORGO Quote, Financials, Valuation and Earnings

Integra LifeSciences Holdings Corp. has a net margin of 14.3% compared to Organogenesis Holdings, Inc.'s net margin of -1.34%. Organogenesis Holdings, Inc.'s return on equity of 0.28% beat Integra LifeSciences Holdings Corp.'s return on equity of -37.15%.

Organogenesis Holdings, Inc. has a consensus price target of $8.50, signalling upside risk potential of 94.95%. On the other hand Integra LifeSciences Holdings Corp. has an analysts' consensus of $15.50 which suggests that it could grow by 18.05%. Given that Organogenesis Holdings, Inc. has higher upside potential than Integra LifeSciences Holdings Corp., analysts believe Organogenesis Holdings, Inc. is more attractive than Integra LifeSciences Holdings Corp..

Organogenesis Holdings, Inc. has a beta of 1.380, which suggesting that the stock is 38.011% more volatile than S&P 500. In comparison Integra LifeSciences Holdings Corp. has a beta of 1.025, suggesting its more volatile than the S&P 500 by 2.536%.

Organogenesis Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra LifeSciences Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organogenesis Holdings, Inc. pays -- of its earnings as a dividend. Integra LifeSciences Holdings Corp. pays out -- of its earnings as a dividend.

Organogenesis Holdings, Inc. quarterly revenues are $150.9M, which are smaller than Integra LifeSciences Holdings Corp. quarterly revenues of $402.1M. Organogenesis Holdings, Inc.'s net income of $21.6M is higher than Integra LifeSciences Holdings Corp.'s net income of -$5.4M. Notably, Organogenesis Holdings, Inc.'s price-to-earnings ratio is 70.39x while Integra LifeSciences Holdings Corp.'s PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organogenesis Holdings, Inc. is 1.21x versus 0.61x for Integra LifeSciences Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of 14.3% compared to Organogenesis Holdings, Inc.'s net margin of -255.85%. Organogenesis Holdings, Inc.'s return on equity of 0.28% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Organogenesis Holdings, Inc. has a consensus price target of $8.50, signalling upside risk potential of 94.95%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -88.5%. Given that Organogenesis Holdings, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Organogenesis Holdings, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Organogenesis Holdings, Inc. has a beta of 1.380, which suggesting that the stock is 38.011% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.

Organogenesis Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Organogenesis Holdings, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Organogenesis Holdings, Inc. quarterly revenues are $150.9M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Organogenesis Holdings, Inc.'s net income of $21.6M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Organogenesis Holdings, Inc.'s price-to-earnings ratio is 70.39x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 12.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organogenesis Holdings, Inc. is 1.21x versus 14.36x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of 14.3% compared to Organogenesis Holdings, Inc.'s net margin of --. Organogenesis Holdings, Inc.'s return on equity of 0.28% beat Palatin Technologies's return on equity of --.

Organogenesis Holdings, Inc. has a consensus price target of $8.50, signalling upside risk potential of 94.95%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Organogenesis Holdings, Inc., analysts believe Palatin Technologies is more attractive than Organogenesis Holdings, Inc..

Organogenesis Holdings, Inc. has a beta of 1.380, which suggesting that the stock is 38.011% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Organogenesis Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organogenesis Holdings, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Organogenesis Holdings, Inc. quarterly revenues are $150.9M, which are larger than Palatin Technologies quarterly revenues of --. Organogenesis Holdings, Inc.'s net income of $21.6M is higher than Palatin Technologies's net income of --. Notably, Organogenesis Holdings, Inc.'s price-to-earnings ratio is 70.39x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organogenesis Holdings, Inc. is 1.21x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of 14.3% compared to Organogenesis Holdings, Inc.'s net margin of --. Organogenesis Holdings, Inc.'s return on equity of 0.28% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Organogenesis Holdings, Inc. has a consensus price target of $8.50, signalling upside risk potential of 94.95%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 2785.41%. Given that Theriva Biologics, Inc. has higher upside potential than Organogenesis Holdings, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Organogenesis Holdings, Inc..

Organogenesis Holdings, Inc. has a beta of 1.380, which suggesting that the stock is 38.011% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.

Organogenesis Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organogenesis Holdings, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Organogenesis Holdings, Inc. quarterly revenues are $150.9M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Organogenesis Holdings, Inc.'s net income of $21.6M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Organogenesis Holdings, Inc.'s price-to-earnings ratio is 70.39x while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organogenesis Holdings, Inc. is 1.21x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.